Communicable Diseases  >>  Recombivax HB (hepatitis B vaccine recombinant)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Recombivax HB (hepatitis B vaccine recombinant) / Merck (MSD)
NCT00414050 / 2006-001638-42: A Study of 2 Doses of a Hepatitis B Vaccine (V232 RECOMBIVAX HB) in Healthy Infants (V232-057)

Completed
3
1718
Europe
Modified Process Hepatitis B Vaccine (Experimental), Hepatitis B Vaccine (Recombinant), RECOMBIVAX HB™, ENGERIX-B®
Merck Sharp & Dohme LLC
Hepatitis B
10/07
10/07
NCT00440531: Study of Recombinant Modified Process Hepatitis B Vaccine in Older Adults (V232-059)(COMPLETED)

Completed
3
540
NA
Comparator: RECOMBIVAX HB™ Hepatitis B Vaccine (Recombinant), Comparator: Modified Process Hepatitis B Vaccine (Experimental), Comparator: ENGERIX-B™ (currently licensed product)
Merck Sharp & Dohme LLC
Hepatitis B
11/07
11/07
NCT01463683: Modified Process Hepatitis B Vaccine in Japanese Young Adults (V232-062)

Completed
3
722
NA
2XP HEPTAVAX™-II SC, RECOMBIVAX HB, HBVAXPRO, 1XP HEPTAVAX™-II SC, 2XP HEPTAVAX™-II IM
Merck Sharp & Dohme LLC
Hepatitis B
11/12
11/12
V419-006, NCT01340937 / 2011-004108-39: A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™

Completed
3
2808
NA
V419, PENTACEL™, Prevnar 13™, RotaTeq™, Recombivax HB vaccine
Merck Sharp & Dohme LLC, MCM Vaccines B.V.
Bacterial Infections, Virus Diseases
12/12
07/13
V419-005, NCT01337167 / 2011-004095-10: Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™

Completed
3
1473
NA
V419, DAPTACEL™, PedvaxHIB™, Prevnar 13™, RotaTeq™, V260, PENTACEL™, Recombivax HB vaccine, ActHIB™
Merck Sharp & Dohme LLC, MCM Vaccines B.V.
Bacterial Infections, Virus Diseases
05/13
05/13

Download Options